•  Introduction
  • RNA therapy: regulatory and developmental challenges
  • Qualifications and toxicity considerations of oligonucleotide-related impurities
  • Conclusion
  • Q&A
Maria Ana Gomez Ferreria
Senior Regulatory Affairs Specialist
Mélissa Bou Jaoudeh
Innovation Product Development Officer
Alex Zwiers

Register to our news and events

Go to our Events to register
Go to our News to get insights

RNA Therapy and potential issues